Participant FAQs

 

What is the MRC CTU and what does it do?

 

 

What are the possible advantages of taking part?

We hope that you will be helped by taking part in this study, but we cannot guarantee this. However, the information we get from this study will help us to improve future treatments for people like you, who have had treatment for cancer, and help us find out more about the overall healthcare benefits that aspirin might provide such as preventing heart disease.

 

What are the possible disadvantages of taking part?

You might experience side effects from the treatment that you take in this study. The most common side effects are:
• Indigestion
• Irritation of the stomach
• More prone to bruising

You will be asked to have a blood test before joining the study and then asked for your permission to have additional blood tests during the study.

You may also be asked to have some extra appointments at the hospital if you take part in the study.

During the study, you will not be able to take drugs such as ibuprofen or Nurofen (non-steroidal anti-inflammatory drugs) on a regular basis.

If you are taking drugs such as citalopram, fluoxetine or paroxetine (Selective serotonin re-uptake inhibitors (SSRIs)), you may be at an increased risk of bleeding during the trial, however this risk is still thought to be small.

If you have private medical insurance or require travel insurance, your policy may be affected. You should check this with your insurance provider.

 

How will my personal data be used?

University College London (UCL) is the sponsor for this study, based in the United Kingdom. UCL will be using information from you and your medical records in order to undertake this study and will act as data controller for this study. UCL will be responsible for looking after your information and using it properly, and will keep identifiable information about you for 25 years after the study has finished.

Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will normally keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally – identifiable information possible.

You can find out more about how we use your information at www.mrcctu.ucl.ac.uk/general/privacy-policy

 

Do I have to take part in the study?

No, it is up to you if you want to take part. You are not obligated to take part in this trial and this will not affect the standard of care you receive.

 

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk

Register a participant

From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

We have been experiencing intermittent issues with the trial websites. In the event of an emergency unblinding outside of office hours (including over the Easter bank holidays), if the usual unblinding links are not working, please telephone +(0)20 7670 4906 or +(0)20 7670 4892 to reach one of the Trial Managers.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India